On the start of phase 1 for KRP-104, therapeutic agent for diabetes, in USA
March 7, 2006
KYORIN Pharmaceutical Co., Ltd. (Ikuo Ogihara, President) filed an IND application (Investigational New Drug Application) for Phase I Clinical Study (Ph 1; Phase 1) on an anti-diabetic agent, KRP-104, that we have newly discovered with the FDA and has initiated administration of KRP-104 to healthy subjects in the United States in this month. The clinical trial on KRP - 104 is the first project for which KYORIN Pharmaceutical Co., Ltd. has filed an IND application with the FDA independently.
KYORIN has been engaged in a collaborative development of KRP - 104 with ActivX Biosciences since 2002, and this project has made it possible to conduct the search for the lead compound as rapidly as we had hoped. This drug is a DPP-IV inhibitor, which shows effect of enhancing insulin secretion and consequently shows glucose-lowering effect by inhibiting the decomposition of insulin secretion hormone. It has a novel mechanism of enhancing insulin secretion during the post-prandial hyperglycemic stage making it a promising candidate for use alone or in combination with other anti-diabetic agents with a reduced risk of hypoglycemia.
Adobe Reader software is required to view and print PDF files. The latest version of Adobe Reader can be downloaded by accessing the Adobe Systems Incorporated website.